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ABSTRACT  We clinically examined Acinetobacter baumannii  pneumonia. Twelve patients 
with A. baumannii  pneumonia were admitted for treatment in Kawasaki Medical School 
Kawasaki Hospital between January 2006 and December 2009. The clinical features of these 
cases have been retrospectively reviewed. The results showed that: (1) hospital-acquired 
pneumonia occurred in elderly patients with underlying diseases such as cerebrovascular 
disease or COPD; (2) the previous administration of antibacterial agents did not become a 
risk factor; (3) there are many drug-resistant strains that are resistant to PIPC and AZT, but 
sensitivity remains to IPM/CS and AMK; (4) prognosis is improved with the administration 
of carbapenem (effective rate 91.7%); (5) there was no outbreak of multidrug-resistant A. 
baumanni . 
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INTRODUCTION
   Acinetobacter baumannii occurs extensively 
in nature, including in soil, water and in the skin 
of healthy individuals; particularly in the axilla 
or between the toes, where perspiration creates a 
moist environment. Generally, it does not cause 
infection in healthy individuals. However, it can 
cause opportunistic infections in the respiratory tract 
and urinary tract, as well as in wounds and blood 
in compromised patients１－３）. Recently, hospital-
acquired infection caused by multidrug-resistant 
A. baumanni has been discussed４－６）. Therefore, 
we examined the clinical features of A. baumanni 
pneumonia in our hospital.
SUBJECTS AND METHODS
Subjects
   The subjects were patients with A. baumannii 
pneumonia admitted for treatment in Kawasaki 
Medical School Kawasaki Hospital between January 
2006 and December 2009.
  A. baumannii  pneumonia was defined as 
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pneumonia with A. baumannii of 107/ml or greater 
detected by a sputum culture.
Methods
   Underlying diseases, antibacterial agents before 
the detection of A. baumannii, susceptibility to 
various antibacterial agents, and the treatment and 
its outcome were retrospectively examined.
RESULTS (Table.1)
Cases
   A. baumannii pneumonia in 12 subjects was 
examined. The subjects included 10 males and 
2 females aged from 66 to 94 years. All subjects 
developed hospital-acquired pneumonia７） diagnosed 
as mild in three, moderate in seven, and severe in 
two. The severe subject’s pneumonia was classified 
as ventilator-associated pneumonia. 
Underlying diseases
   Underlying diseases included cerebrovascular 
disease in seven subjects, COPD in two, idiopathic 
interstitial pneumonia in one, old pulmonary 
tuberculosis in one, and chronic rheumatoid arthritis 
in one.
Previous administration of antibacterial agents 
  Antibacterial agents were  a d m i n i s t e r e d  t o 
three of the 12 patients before the detection of 
A. baumannii. Administered antibacterial agents 
included sulbactm / ampicillin (SBT /ABPC) in two 
cases and piperacillin (PIPC) in one.
Susceptibility to various antibacterial agents
   Six (50%) of the 12 strains were resistant to 
aztreonam (AZT), five (41.7%) strains were 
resistant to PIPC, two (16.7%) strains were resistant 
to levofloxacin and one (8.3%) strain was resistant 
to ceftazidime (CAZ). All strains were sensitive 
to imipenem / cilastain (IPM / CS) and amikacin 
(AMK).
Treatment, Clinical efficacy and Bacteriological 
efficacy
  The choice of drugs were meropenem (MEPM) in 
four cases, IPM/CS in three, CAZ in two, and SBT 
/ ABPC, sulbactam / cefoperazone (SBT / CPZ) and 
ciprofloxacin (CPFX) in one each.
Table 1.　The clinical features of cases with Acinetobacter baumannii pneumonia
 
Cases Age Gender
Classiﬁcation
 of
pneumonia
Underlying
diseases 
Previous
administration
of antibiotics
Susceptibility A. baumannii to antibiotics
Treatment Clinicalefﬁcacy
Bacteriological
efﬁcacyPIPC CAZ IPM AZT AMK LVFX
1 66 M HAP*(moderate) Cerebrovascular disease （－） S S S S S S
SBT/
ABPC Good Eradicated
2 68 M 〃 　( 〃 ) 〃 （－） S S S S S S CAZ 〃 〃
3 76 M 〃 　( 〃 ) I I P s （－） S S S Ⓡ S S IPM/CS 〃 〃
4 78 M 〃 　( 〃 ) COPD （－） S S S S S S MEPM 〃 〃
5 80 F 〃　(mild) RA （－） S S S Ⓡ S S MEPM 〃 〃
6 81 F 〃　(mild) Cerebrovascular disease （－） Ⓡ Ⓡ S Ⓡ S S
SBT/
CPZ 〃 Unknown
7 83 M 〃 (severe),VAP** 〃 SBT/ABPC Ⓡ S S Ⓡ S S CAZ 〃 Eradicated
8 85 M 〃 (moderate) 〃 （－） S S S S S S MEPM 〃 〃
9 86 M 〃　( 〃 ) 〃 SBT/ABPC S S S S S S IPM/CS 〃 〃
10 86 M 〃　(mild) Old pulmonary tb. （－） Ⓘ S S S S S CPFX 〃 Unknown
11 94 M 〃 (moderate) Cerebrovascular disease （－） Ⓡ S S Ⓘ S Ⓘ IPM/CS 〃 〃
12 90 M 〃 (severe) COPD P I PC Ⓘ S S Ⓡ S Ⓡ MEPM Poor（death） Persisted
HAP*  : hospital - acquired pneumonia 　
VAP** : ventilator -associated pneumonia
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  The medication was clinically effective in 11 of 
the 12 subjects and non-effective in one (effective 
rate 91.7%). The non-effective case was a severely 
affected subject, who died due to pneumonia.
  Bacterial eradication was achieved in nine 
traceable subjects and but not in one and the 
deceased subject (eradication rate 88.9%).
DISCUSSION
   A. baumannii pneumonia is a hospital-acquired 
pneumonia in many cases and extremely rare in 
healthy individuals. It occurs in elderly patients with 
underlying diseases, which is consistent with the 
conventional reports１－６）. 
   It is pointed out that A. baumannii pneumonia is 
important as the causative pathogen in ventilator-
associated pneumonia３,８,９）: among our subjects, 
one was classified as ventilator-associated 
pneumonia.
   The occurrence of A. baumannii pneumonia was 
sporadic and there was no evidence of an outbreak 
in our hospital.
   In the literature, severe community-acquired 
pneumonia is sometimes reported10－15）. However, 
in our subjects there was no community-acquired 
pneumonia.
   Leung et al.８） reported that the underlying 
diseases in A. baumanni pneumonia includes COPD, 
at a high frequency, and cerebrovascular diseases. 
This is consistent with our results.
   It is reported that previous administration of 
antibacterial agents is a risk factor for the onset of 
A. baumanni pneumonia or sepsis３,８）. However, 
only three out of our 12 subjects were previously 
administered antibacterial agents before the 
detection of A. baumannii. This means that the 
previous administration of antibacterial agents 
was not a risk factor in the onset of A. baumanni 
pneumonia in our cases. 
   With regards to the susceptibility to various 
antibacterial agents, many strains were resistant to 
PIPC, AZT, CAZ and LVFX. However, all strains 
were sensitive to IPM / CS and AMK. 
   Recently, multidrug-resistant A. baumanni with 
resistance to carbapenem or aminoglycoside has 
become a serious problem in hospital-acquired 
infections４,６）. However, in our subjects, resistance 
against IPM / CS and AMK was not observed. This 
fact might contribute to an improved prognosis with 
an efficacy rate of 91.7% and an eradication rate of 
88.9%. There seems to be no contamination of the 
multidrug-resistant A. baumanni in our hospital,
   For the treatment, the choice of drugs included 
carbapenem in seven cases（MEPM in four, and 
IPM/CS in three）,which was most frequently used, 
followed by cephem  in three (CAZ in two, and 
SBT/CPZ in one). These choices may be appropriate 
in terms of the hospital-acquired pneumonia 
guideline７）, and sensitivity. 
   The case of death was a severely affected subject. 
There were no deaths among the mild or moderate 
subjects. The validity of the severity classification 
using life prognosis in the JRS guidelines for the 
management of hospital-acquired pneumonia７） was 
demonstrated.
   The A. baumanni pneumonia we treated is 
summarized as follows: (1) hospital-acquired 
pneumonia occurred in elderly patients with 
underlying diseases such as cerebrovascular 
disease or COPD; (2) previous administration 
of antimicrobial agents was not a risk factor; (3) 
there are many strains resistant to PIPC and AZT, 
but sensitivity remains to IPM/CS and AMK;  (4) 
prognosis was improved with the administration of 
carbapenem (effective rate 91.7%); (5) there was no 
outbreak of multidrug-resistant A. baumanni in our 
hospital.
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